AMP-886

N/A

Report date: 2025/06/11 11:19:42
NME

Base Information

Drug NameAMP-886
Drug Alias Namedual focal adhesion kinase/VEGFR-3 inhibitors (Cancer Therapeutics CRC)triple FAK/VEGF3/FLT3 inhibitor (Cancer Therapeutics CRC)dual FAK/VEGFR-3 inhibitors (Cancer Therapeutics CRC)triple FAK/VEGF3/FLT3 inhibitor (Amplia Therapeutics)CTx-294886 +[7] 
ClassificationSmall molecules
Mechanisms of ActionVascular endothelial growth factor receptor 3 antagonistsAnticancer protein kinase inhibitorsTyrosine-protein kinase receptor FLT3 inhibitors +[4] 
TargetsVascular endothelial growth factor receptor 3Tyrosine-protein kinase receptor FLT3Focal adhesion kinase
Therapy Area/IndicationsFibrosisWet age-related macular degenerationNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia and New ZealandUnited Kingdom
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCancer Therapeutics CRC Pty Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAmplia Therapeutics Ltd
Inactive CompaniesCancer Therapeutics CRC Pty LtdCancer Research TechnologyAlchemia Ltd
Active IndicationsFibrosisWet age-related macular degenerationNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A